Preventive Effect of Iganidipine on Renal and Cerebral Injuries in Salt-Induced Hypertension

Iganidipine, a new water-soluble calcium antagonist, was administered at a nonhypotensive dose (NHD) of 0.3 mg/kg/day, a moderate-hypotensive dose (MHD) of 1.0 mg/kg/day, and a sustained-hypotensive dose (SHD) of 3.0 mg/kg/day to Dahl salt-sensitive (Dahl-S) rats fed a high-salt diet for 8 weeks. Th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hypertension 1997-08, Vol.10 (8), p.869-878
Hauptverfasser:	Shirahase, Hiroaki, Wada, Katsuo, Uehara, Yoshio, Nakamura, Shohei, Ichikawa, Atsuko
Format:	Artikel
Sprache:	eng
Schlagworte:	angiotensin II Animals Antihypertensive agents Biological and medical sciences Blood Pressure - drug effects Calcium Channel Blockers - therapeutic use Cardiovascular system cerebral infarction Cerebral Infarction - etiology Cerebral Infarction - pathology Cerebral Infarction - prevention & control Dahl salt-sensitive rat Eicosanoids - urine Glomerular Filtration Rate glomerulosclerosis Glomerulosclerosis, Focal Segmental - pathology Glomerulosclerosis, Focal Segmental - prevention & control Hypertension - complications Iganidipine Kidney Tubules - pathology Male Medical sciences Neurotransmitter Agents - blood Pharmacology. Drug treatments Piperazines - therapeutic use prostaglandin Pyridines - therapeutic use Rats Rats, Inbred Strains Renal Artery - pathology Renal Insufficiency - etiology Renal Insufficiency - pathology Renal Insufficiency - prevention & control Sodium Chloride, Dietary
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!